- The FDA has designated Forte Biosciences's (NASDAQ:FBRX) FB-401 for fast track review for the treatment of atopic dermatitis (also known eczema).
- FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa.
- Atopic dermatitis is an inflammatory skin condition that makes skin red and itchy.
- Enrollment is currently underway for Phase 2 trial of FB-401 in atopic dermatitis.
- https://seekingalpha.com/news/3625750-forte-biosciences-nabs-accelerated-review-tag-for-fbminus-401-in-u-s
Monday, October 26, 2020
Forte Biosciences nabs accelerated review tag for FB-401 in U.S.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.